Clinical trials: Untreated Follicular Lymphoma
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Lymphoma, Follicular
Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)
Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogenic signal is present.
- Trial name
- NCT00427856
- Testing
- Obatoclax mesylate, Rituximab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Gemin X
Leukemia, Lymphoma
Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00026351
- Testing
- rituximab, pentostatin
- Where
- 5 sites in United States
- Sponsor
- Pharmatech Oncology
Follicular Lymphoma
Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma
This is a phase II clinical trial in patients who have not received systemic treatment for follicular non-Hodgkin's lymphoma. The study combines rituximab, an approved drug for this disease, with AT-101, an experimental drug.
- Trial name
- NCT00440388
- Testing
- AT-101, Rituximab
- Where
- 28 sites in United States
- Volunteers
- 23 people
- Sponsor
- Ascenta Therapeutics
Follicular Lymphoma, Lymphoma, Follicular
Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)
This study will treat follicular lymphoma patients who have not received previous treatment with R-CVP. Half of the patients will receive Zevalin after R-CVP and the other half will receive only R-CVP.
- Trial name
- NCT00384111
- Testing
- Zevalin Therapeutic Regimen, R-CVP
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Follicular Lymphoma
Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma
This Phase II trial studies the overall tumor response of vaccine therapy in patientswith previously untreated Stage III or IV, asymptomatic, non-bulky follicular lymphoma.
- Trial name
- NCT02194751
- Testing
- Oncoquest-L vaccine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- XEME Biopharma Inc.
Follicular Lymphoma
Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma
The primary objective of the current study is to demonstrate the equivalent efficacy of rituximab (DRL_RI) and MabThera® in subjects with Low Tumor Burden Follicular Lymphoma (LTB-FL).
- Trial name
- FLINTER (NCT03976102)
- Testing
- DRL_RI (Proposed rituximab biosimilar), MabThera®
- Where
- 4 sites in United States
- Volunteers
- 317 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Lymphoma, Follicular
Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients
To investigate the efficacy in two dose regimens of ofatumumab in combination with CHOP (cyclophosphamide,doxorubicin, vincristine,prednisolone) in previously untreated patients with Follicular Lymphoma (FL)
- Trial name
- MUNIN (NCT00494780)
- Testing
- Ofatumumab, Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- GlaxoSmithKline
Follicular Lymphoma
GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)
The purpose of this study is to demonstrate comparability of the ORR in patients with previously untreated, advanced stage FL who receive GP2013-treatment to patients who receive MabThera-treatment.
- Trial name
- ASSIST_FL (NCT01419665)
- Testing
- GP2013, rituximab
- Where
- 153 sites in Argentina, Australia and 24 more
- Volunteers
- 629 people
- Sponsor
- Sandoz
CD20+ Follicular Lymphoma
A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)
A Two-arm, Phase 1b/2 Study of duvelisib Administered in Combination with Rituximab or Obinutuzumab in Subjects with Previously Untreated CD20+ Follicular Lymphoma.
- Trial name
- NCT02391545
- Testing
- Duvelisib, Rituximab, Obinutuzumab
- Where
- 21 sites in United States, Belgium and 4 more
- Volunteers
- 55 people
- Sponsor
- SecuraBio
Follicular Lymphoma
Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)
To evaluate the effectiveness and safety of obinutuzumab in clinical routine in 1L FL measured by the % of relapse within 24 months from start of therapy.
- Trial name
- URBAN (NCT04034056)
- Testing
- Obinutuzumab
- Where
- 46 sites in Italy
- Volunteers
- 299 people
- Sponsor
- Hoffmann-La Roche
Follicular Lymphoma (FL)
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma.
- Trial name
- OLYMPIA-2 (NCT06097364)
- Testing
- Odronextamab, Rituximab, Cyclophosphamide
- Where
- 145 sites in United States, Australia and 15 more
- Volunteers
- 733 people
- Sponsor
- Regeneron Pharmaceuticals
Follicular Lymphoma (FL)
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all…
- Trial name
- EPCORE™FL-2 (NCT06191744)
- Testing
- Epcoritamab, Prednisone, Rituximab
- Where
- 266 sites in United States, Australia and 30 more
- Volunteers
- 1,095 people
- Sponsor
- Genmab